Clostridial gas gangrene: Evidence that α and θ toxins differentially modulate the immune response and induce acute tissue necrosis

Journal of Infectious Diseases

Volumn 176, Issue 1, 1997, Pages 189-195

  Stevens, Dennis L ^a   Tweten, Rodney K ^b   Awad, Milena M ^b   Rood, Julian I ^b   Bryant, Amy E ^b  

^a Boise VA Medical Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; GAS GANGRENE; HISTOPATHOLOGY; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; TISSUE NECROSIS; TOXIN ANALYSIS;

EID: 0031007249     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514022     Document Type: Article

References (28)

1. Smith LDS. Clostridium perfringens. In: Smith LDS, ed. The pathogenic anaerobic bacteria. Springfield, IL: CC Thomas, 1975:115-76.
2. Finegold SM, George WL, Mulligan ME. Anaerobic infections. Part I. Dis Mon 1985;31:50-7.
3. MacLennan JD. The histotoxic clostridial infections of man. Bacteriologic Rev 1962;26:177-276.
4. Darke SG, King AM, Slack WK. Gas gangrene and related infection: classification, clinical features and aetiology, management and mortality. A report of 88 cases. Br J Surg 1977;64:104-12.
5. Bullen JJ. Role of toxins in host-parasite relationships. In: Montie TC, Kadis S, Ajl SJ, eds. Microbial toxins. London: Academic Press, 1970: 233-75.
6. Ispolatovskaya MV. Type A Clostridium perfringens toxin. In: Kadis S, Montie TC, Ajl SJ, eds. Microbial toxins. New York: Academic Press, 1972:109-58.
7. Stevens DL, Troyer BE, Merrick DT, Mitten JE, Olson RD. Lethal effects and cardiovascular effects of purified α- and θ-toxins from Clostridium perfringens. J Infect Dis 1988;157:272-9.
8. Asmuth DA, Olson RD, Hackett SP, et al. Effects of Clostridium perfringens recombinant and crude phospholipase C and θ toxins on rabbit hemodynamic parameters. J Infect Dis 1995;172:1317-23.
9. Smith LDS. Virulence factors of Clostridium perfringens. Rev Infect Dis 1979;1:254-60.
10. Mollby RC, Wadstrom T. Purification of phospholipase C (alpha-toxin) from Clostridium perfringens. Biochim Biophys Acta 1973;321:569-84.
11. Harris RW, Sims PJ, Tweten RK. Evidence that Clostridium perfringens theta-toxin induces colloid-osmotic lysis of erythrocytes. Infect Immun 1991;59:2499-501.
12. Awad MM, Bryant AE, Stevens DL, Rood JI. Virulence studies on chromosomal α-toxin and θ toxin mutants constructed by allelic exchange provide genetic evidence for the essential role of α-toxin in Clostridium perfringens - mediated gas gangrene. Mol Microbiol 1995;15:191-202.
13. Ninomiya M, Matsushita O, Minami J, Sakamoto H, Nakano M, Okabe A. Role of alpha-toxin in Clostridium perfringens infection determined by using recombinants of C. perfringens and Bacillus subtilis. Infect Immun 1994;62:5032-9.
14. Stevens DL, Mitten J, Henry C. Effects of α and θ toxins from Clostridium perfringens on human polymorphonuclear leukocytes. J Infect Dis 1987; 156:324-33.
15. Stevens DL, Gibbons AE, Bergstrom RA. Ultrastructural changes in human granulocytes induced by purified exotoxins from Clostridium perfringens. Washington, DC: American Society for Microbiology, 1989.
16. Bryant AE, Bergstrom R, Zimmerman GA, et al. Clostridium perfringens invasiveness is enhanced by effects of theta toxin upon PMNL structure and function: the roles of leukocytotoxicity and expression of CD11/ CD18 adherence glycoprotein. FEMS Immunol Med Microbiol 1993; 7:321-36.
17. Whatley RE, Zimmerman GA, Stevens DL, Parker CJ, McIntyre TM, Prescott SM. The regulation of platelet activating factor synthesis in endothelial cells - the role of calcium and protein kinase C. J Biol Chem 1989;11:6325-33.
18. Bryant AE, Stevens DL. Phospholipase C and perfringolysin O from Clostridium perfringens upregulate endothelial cell - leukocyte adherence molecule 1 and intercellular leukocyte adherence molecule 1 expression and induce interleukin-8 synthesis in cultured human umbilical vein endothelial cells. Infect Immun 1996;64:358-62.
19. Tweten RK. Cloning and expression in Escherichia coli of the perfringolysin O (theta-toxin) gene from Clostridium perfringens and characterization of the gene product. Infect Immun 1988;56:3228-34.
20. Tweten RK. Nucleotide sequence of the gene for perfringolysin O (thetatoxin) from Clostridium perfringens: significant homology with the genes for streptolysin O and pneumolysin. Infect Immun 1988;56:3235-40.
21. Tso JY, Siebel C. Cloning and expression of the phospholipase C gene from Clostridium perfringens and Clostridium bifermentans. Infect Immun 1989;57:468-76.
22. Layne E. Spectrophotometric and turbidimetric methods for measuring proteins. In: Colowick SP, Kaplan ND, eds. Methods in enzymology. New York: Academic Press, 1957:447-54.
23. Sato H. Monoclonal antibodies against bacteria. 3rd ed. New York: Academic Press, 1986.
24. Stevens DL, Maier KA, Laine BM, Mitten JE. Comparison of clindamycin, rifampin, tetracycline, metronidazole, and penicillin for efficacy in prevention of experimental gas gangrene due to Clostridium perfringens. J Infect Dis 1987;155:220-8.
25. Stevens DL, Laine BM, Mitten JE. Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens. Antimicrob Agents Chemother 1987;31: 312-6.
26. Rudbach JA, Cantrell JL, Ulrich JT. Molecularly engineered immunostimulators. Tech Adv Vaccine Dev 1988;443-54.
27. Stevens DL, Bryant AE, Adams K, Mader JT. Evaluation of hyperbaric oxygen therapy for treatment of experimental Clostridium perfringens infection. Clin Infect Dis 1993;17:231-7.
28. McNee JW, Dunn JS. The method of spread of gas gangrene into living muscle. Br Med J 1917;1:727-9.